OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has awarded Chief Scientific Officer Raj Patil 5,000,000 options with an exercise price of 6.25 pence per share, recognizing his contribution to the recent IND filing for OK-101, aimed at treating dry eye disease. The options vest immediately and have a five-year lifespan. This move highlights the company's advancement in developing therapies for the significant unmet needs in the dry eye market, which is valued in the billions. The announcement complies with UK MAR regulations.
OKYO Pharma Ltd (NASDAQ: OKYO) announced a Key Opinion Leader webinar on November 14, 2022, regarding its potential treatment, OK-101, for inflammatory dry eye disease. The event features KOL Pedram Hamrah, MD, discussing preclinical data on OK-101's efficacy. The company aims to address a significant market need in dry eye therapies and will provide updates on its Phase 2 trial for OK-101, a lipid-conjugated peptide targeting ocular pain and inflammation.
OKYO Pharma Limited (NASDAQ: OKYO) announced its CEO, Dr. Gary Jacob, will be featured on The RedChip Money Report on Bloomberg TV on September 10, 2022. The interview will cover the company's NASDAQ listing, plans for a Phase 2 study for Dry Eye Disease, and expectations for top-line data. This access expands OKYO's visibility as it operates in the biotechnology sector, focusing on new treatments for inflammatory dry eye diseases and ocular pain.
OKYO Pharma Limited (NASDAQ: OKYO) announced an upcoming interview with CEO Dr. Gary Jacob on the RedChip Money Report airing on Bloomberg TV on September 10, 2022, at 7 p.m. ET. The interview will cover the company's NASDAQ listing and plans for a Phase 2 study for Dry Eye Disease, including anticipated top-line data. OKYO focuses on developing novel treatments for inflammatory dry eye diseases and chronic pain, and is listed on both NASDAQ and the London Stock Exchange.
On September 7, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that all resolutions at its Annual General Meeting were successfully passed. The voting results showed overwhelming support, with key resolutions such as the approval of the report and accounts receiving 99.99852% approval. Shareholders, totaling 1,415,040,468 ordinary shares, participated actively in the voting process. The resolutions included the re-election of directors and the appointment of auditors, reflecting strong governance practices and shareholder confidence in the company's direction.
OKYO Pharma Limited is gearing up for a Q4 2022 IND filing for OK-101, targeting dry eye disease (DED) and supported by AmbioPharm. Following a successful pre-IND meeting with the FDA in Q1 2022, the Phase 2 trial is set to commence in Q1 2023, designed to expedite market entry. OK-101, a lipid-peptide analog, showcases potent anti-inflammatory properties in animal models, addressing a significant unmet need in the multibillion-dollar DED market.
OKYO Pharma Limited (NASDAQ: OKYO) announced its audited results for the year ending March 31, 2022. They reported a comprehensive loss of £3,976k and a cash balance of £2,056k. The company is advancing its lead candidate OK-101 for dry eye disease (DED) and plans to file an IND by Q4 2022, followed by a Phase 2 trial in early 2023. Preclinical studies showed significant efficacy for OK-101 in reducing corneal permeability and pain, with potential future evaluations for uveitis and allergic conjunctivitis.
On June 9, 2022, OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that non-executive director Willy Simon acquired 361,195 ordinary shares at prices ranging from £0.02679 to £0.0284 each. This market purchase indicates Simon's confidence in the company's growth potential in the dry eye care sector. OKYO Pharma is focused on developing novel treatments for dry eye diseases and ocular pain, with its lead candidate, OK-101, demonstrating promising anti-inflammatory effects in preclinical studies.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited acquired 5,800,000 ordinary shares at £0.0625 each on May 19, 2022. This purchase increases Gabriele Cerrone's beneficial interest from 39.64% to 40.06%. However, dilution from a recent offering reduces his holdings to 39.08%. The company's focus on developing novel molecules for treating inflammatory dry eye diseases remains ongoing, highlighting its commitment to addressing significant medical needs in the eye care market.
OKYO Pharma announced the closing of its public offering of 625,000 American Depository Shares (ADSs) at $4.00 per share, totaling $2.5 million in gross proceeds. The funds will be utilized to advance the IND filing for OK-101 to treat dry eye disease (DED), support an initial Phase 2 clinical trial, and for general corporate purposes. ThinkEquity served as the sole book-running manager. This offering follows the effective registration statement filed with the SEC on May 16, 2022.